132 studies (12 from unattributed sources) on Retatrutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Hk Peptides | 137 | 99.77% | View COA → |
| Lilipeptide | 131 | 99.55% | View COA → |
| Shanghai Sigma Audley Ssa | 126 | 99.45% | View COA → |
| Qing Li Peptide | 116 | 99.62% | View COA → |
| Nexaph | 115 | 99.41% | View COA → |
| Bfflist Amo | 105 | 99.71% | View COA → |
| Zlz Peptide | 96 | 99.78% | View COA → |
| Peptide Sciences | 84 | 99.64% | View COA → |
Recent certificates: #16690 (99.524%) · #23591 (99.862%) · #16764 (99.522%) · #16766 (99.876%) · #21928 (99.9%) · #21929 (99.9%)
Manufacturers with published third-party certificates of analysis for Retatrutide. Open a vendor to see every batch we've verified.
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
This review critically underscores the importance of a holistic and integrated approach to weight management when utilizing powerful pharmacological tools like GLP-1 RAs. Preserving muscle mass is not merely an aesthe…
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. Th…
This review underscores the critical importance of understanding glucagon's pleiotropic (multiple) actions beyond glucose regulation. By elucidating shared mechanistic pathways, it provides a robust scientific rationa…
This review underscores the transformative potential of novel GLP-1-based medications to significantly advance the treatment of Type 2 Diabetes and Obesity. The enhanced efficacy in weight loss and glycemic control, c…
This publication is crucial because it details the blueprint for a comprehensive clinical program that could significantly expand the therapeutic options for several widespread and debilitating conditions. The multi-i…
This comprehensive review highlights the significant therapeutic potential of GLP-1 agonists as a multi-faceted treatment for PCOS, addressing not only metabolic dysfunction like insulin resistance and obesity but als…
This trial represents a pivotal step in exploring Retatrutide's potential beyond its established metabolic benefits, specifically targeting the complex pathology of CKD progression. If the TRANSCEND-CKD trial demonstr…
These findings underscore the critical importance of patient-reported outcomes in evaluating novel therapies, revealing that retatrutide offers substantial benefits beyond just weight loss. The observed improvements i…
This review underscores the transformative potential of engineered multi-agonists in the treatment landscape for obesity and metabolic disorders. By providing a conceptual blueprint for these advanced therapeutics, it…
This comprehensive systematic review provides a critical evidence base for clinicians and patients regarding the expected gastrointestinal side effects of anti-obesity medications. Understanding these common adverse e…
This review provides a critical roadmap for clinicians and researchers, consolidating the evidence for GLP-1 RAs as a cornerstone of modern obesity treatment. Understanding both their profound benefits and inherent li…
The findings from this review underscore a transformative era in the management of diabetic kidney disease, where novel therapies are significantly improving patient prognosis and quality of life. These advancements a…
This review provides a crucial, up-to-date resource for healthcare providers, offering a clear understanding of the current landscape of obesity pharmacotherapy. It underscores the paradigm shift towards highly effect…
Repurposing glucagon represents a significant paradigm shift in the treatment of obesity and type 2 diabetes, offering a novel and powerful approach beyond current single-target therapies. By harnessing its beneficial…
This comprehensive meta-analysis provides compelling evidence that Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, offers multi-faceted benefits for patients with the complex comorbidity of…
These advancements collectively represent a significant leap forward in nephrology, offering new hope for patients with various kidney conditions. The expansion of complement inhibitors and the efficacy of GLP-1 recep…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
The development of the WES represents a significant advancement in the assessment of the emotional dimensions of weight. This validated and reliable tool provides clinicians and researchers with a much-needed instrume…
This systematic review provides compelling evidence that next-generation incretin agonists offer superior efficacy for both weight management and glycemic control in overweight and obese individuals. The substantial w…
The findings from this study are profoundly significant, as they identify retatrutide as a potentially superior therapeutic agent for MC4R-deficient obesity, a condition notoriously difficult to manage. This MC4R defi…
Retatrutide's ability to simultaneously address obesity, insulin resistance, and multiple facets of MASH pathology is highly promising. This multi-target approach could offer a superior therapeutic strategy for a comp…
This comprehensive overview highlights Retatrutide's potential as a transformative therapeutic agent for managing the complex interplay of type 2 diabetes and obesity, offering a more holistic approach to metabolic he…
This network meta-analysis provides crucial comparative data on the efficacy and safety of various Glucagon Receptor Agonists, offering a more nuanced understanding than individual trials alone. The findings can help …
The development of Retatrutide represents a significant advancement in the pharmacological treatment of obesity and type 2 diabetes, offering a highly potent and comprehensive therapeutic option. Its unique triple-ago…
The findings from this Phase 1 study are critically important for the future development of LY3437943. Understanding the impact of hepatic impairment on drug pharmacokinetics is essential for establishing safe and eff…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…
This review underscores the critical need for integrated care models that combine pharmacological treatment with tailored nutritional guidance. Implementing personalized dietary plans alongside AOMs could significantl…
Free, no account — handy when you're working with Retatrutide.